% | $
Quotes you view appear here for quick access.

Talon Therapeutics, Inc. Message Board

  • dinepat203 dinepat203 Mar 22, 2012 10:51 AM Flag

    Might workout with Merck, BRISTOL MAYER S, TEKIMERA?

    Merck has access to certain Tekmira delivery technology for the delivery of small interfering RNAs (siRNAs). Currently, there is no active research program underway with Merck; however, Tekmira is eligible to receive up to US$17 million in milestones and royalties on each and every RNAi product that Merck advances using Tekmira’s technology.

    Takeda and Tekmira expanded their research collaboration in the first quarter of 2010. As part of the expanded collaboration, Takeda will evaluate new Tekmira LNP formulations to deliver siRNA molecules provided by Takeda.

    Bristol-Myers Squibb
    In the second quarter of 2010, Tekmira entered into a multi-year, target validation agreement with Bristol-Myers Squibb. Tekmira will provide LNP formulations of siRNA provided by Bristol-Myers Squibb to silence target genes of interest. Bristol-Myers paid Tekmira US$3.0 million concurrent with the signing of the agreement. Importantly, Bristol-Myers Squibb will share of the target validation data it generates and Tekmira can use this data to develop its own RNAi therapeutic products.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You should Takmira,Takenda ,Hana, GALE, extra , one name I going to stand out, TAKMIRA which is. Con of a company and a major share holder of the above, it does not care about it share holders, dilution nd name changing are he order of the day.